The Children’s Hospital of Philadelphia was ranked No. 1 in more specialties than any other hospital in the nation, earning it top honors in U.S.News & World Report’s 2012-13 Honor Roll of Best Children’s Hospitals. CHOP is one of only 12 pediatric hospitals named to U.S.News’ elite Honor Roll. Learn more about the U.S.News rankings.
The University of Pennsylvania School of Medicine, CHOP’s academic affiliate, is ranked No. 1 in the nation for Pediatrics in U.S.News & World Report’s most recent annual survey of research-oriented U.S. medical schools. All CHOP physicians serve on the faculty of the Penn School of Medicine. The medical school rankings are based on assessments of deans of peer medical schools across the country.
Parents magazine rated The Children's Hospital of Philadelphia No. 1 in the nation in its 2013 report of 10 Best Children’s Hospitals. In addition to the overall ranking, Parents magazine also ranked CHOP’s Cancer Center and emergency medicine division No. 1 in the nation. The Cardiac Center tied for first, neonatology ranked second and orthopedics and pulmonology ranked third.
Parents surveyed pediatric hospitals across the country to determine where the more than three million children hospitalized each year receive the best care possible. Read more about this ranking.
Seven CHOP physicians have been elected members of the Institute of Medicine, a highly-regarded organization that recognizes individuals who have made significant contributions to the field of medicine and educates the government and the public about health and medical issues. Membership recognizes the height of professional achievement and commitment to service and is bestowed on those at the top of their field.
The Children’s Hospital of Philadelphia was awarded Magnet Status for Nursing Excellence, the nursing profession’s highest national recognition, by the American Nursing Credentialing Center (ANCC), an arm of the American Nurses Association, in 2004, and received recertification in 2008. Only 2 to 3 percent of hospitals nationwide have achieved this coveted status. Children's Hospital was the first pediatric hospital in Pennsylvania to receive Magnet status.
The Children’s Hospital of Philadelphia is the first pediatric hospital recognized as a Center of Excellence by Fertile Hope for its commitment to educate cancer patients and their families about the risk of infertility following cancer treatment and to offer potential ways to preserve fertility. Fertile Hope is a national initiative dedicated to providing reproductive information, support and hope to cancer patients and survivors whose medical treatments present the risk of infertility.
Children’s Hospital was designated a Human Genome Center by the National Institutes of Health and was awarded a major federal grant for the mapping of chromosome 22 in the early 90s. Children’s Hospital researchers completed mapping chromosome 22 in 1999, making it the first human chromosome to be fully sequenced. Defects in genes on chromosome 22 are implicated in certain leukemias and other pediatric tumors, mental retardation, numerous birth defects and the 22q11 deletion syndrome.
The Children’s Hospital of Philadelphia earned three-year Accreditation by the Joint Commission on Heath Care Organizations for 2004 – 2007, which recognizes compliance with national standards for excellence in providing quality patient care within organized healthcare delivery settings. Joint Commission accreditation and certification is recognized nationwide as a symbol of quality that reflects an organization’s commitment to meeting performance standards. Read more about this accreditation.
The National Committee for Quality Assurance (NCQA) has announced that The Children’s Hospital of Philadelphia (CHOP) has earned accreditation as an Accountable Care Organization (ACO). CHOP is the only children’s hospital in the country to earn accreditation and is among the first five organizations to be accredited nationally. Learn more about what it means to be ACO accredited.
One of only 66 employers in the country to receive the 2010 Best Employers for Healthy Lifestyles award from the National Business Group on Health (NBGH), a nonprofit association of large employers. CHOP received a Gold Award from NBGH, for creating cultural and environmental changes that support employees who are committed to long-term behavior changes. In 2009, the Hospital was recognized with a Silver Award, for employers that have launched significant programs and services to promote living a healthier lifestyle.
CHOP was one of only 20 large employers named to The Philadelphia Inquirer’s Top Workplaces 2011, a recognition based on results from an employee survey ranking the best employers in the Philadelphia region.
The nation's first children’s hospital, CHOP has been the birthplace of many firsts in pediatric medicine and has fostered medical discoveries and innovations that have improved pediatric healthcare and saved countless children’s lives.
Among pediatric hospitals in the U.S., The Children’s Hospital of Philadelphia Research Institute ranks as one of the highest in funding from the National Institutes of Health (NIH).
The Children’s Hospital of Philadelphia was the first children’s hospital to develop a formal training program in pediatrics, which it founded in 1877. Today, CHOP has one of the largest pediatric residency training programs in the nation, with nearly 150 residents, and is a leader in pediatric medical education for the country.
In 1962, under the leadership of C. Everett Koop, MD, then CHOP surgeon-in-chief and later Surgeon General of the United States, the Hospital established the first surgical neonatal intensive care unit in the nation. Nearly 30 years prior to the NICU’s founding, CHOP clinicians developed the Isolette, the first closed incubator for newborns. Today, CHOP’s Newborn/Infant Intensive Care Unit is one of the largest in the U.S. and treats the most seriously ill newborns and infants.
The Children’s Hospital of Philadelphia was the first to use balloon catheter, a lifesaving technique to treat neonates with transposition of the great arteries. The procedure was invented in 1966 by William Rashkind, MD, then chief of the Devision of Cardiology and renowned as the “father of the field of interventional cardiology.” Dr. Rashkind also invented devices to close atrial septal defects and persistent patent ductus arteriosus.
Today, the Hospital’s Cardiac Center is one of the world’s largest and most recognized programs for treatment of congenital and acquired heart disease, providing comprehensive care from before birth through adulthood.
CHOP’s Center for Fetal Diagnosis and Treatment is a pioneer in the field of fetal medicine. Since the Center’s founding more than 15 years ago, our team has translated scientific discovery into lifesaving treatments for numerous birth defects, improving the lives of countless children. Our team continues to explore cutting-edge surgical and minimally invasive techniques, as well as gene and stem cell therapies for treating conditions previously thought untreatable while babies are still in the womb.
A research team co-led by CHOP surgeon-in-chief and director of the Center for Fetal Diagnosis and Treatment N. Scott Adzick, MD, recently established fetal surgery as a new standard of care for spina bifida, the most common neurologic birth defect. The team at the Center pioneered the fetal repair technique for spina bifida and has the greatest depth of collective experience in prenatal spina bifida surgery in the world.
CHOP’s Center for Fetal Diagnosis and Treatment is home to the world’s first delivery unit within a pediatric hospital created specifically for pregnancies complicated by birth defects. The Garbose Family Special Delivery Unit facilitates the most advanced care for neonates immediately upon delivery, and allows mother and baby to remain together in the same hospital for the duration of their care.
Over the course of its long history, researchers at Children’s Hospital have developed the first vaccines for mumps, whooping cough, rubella and influenza and discovered the cause of infectious mononucleosis. Most recently, they created the rotavirus vaccine, which has the potential to save hundreds of thousand of lives each year worldwide.
The Congenital Hyperinsulinism (HI) Center at The Children’s Hospital of Philadelphia is one of few programs worldwide to focus on developing new therapies for this rare condition, which causes severe, persistent hypoglycemia. CHOP has a 95 percent surgical cure rate for focal HI, the most common form of the disease.
Our Center for Thoracic Insufficiency Syndrome is led by Robert Campbell, M.D., inventor of the VEPTR (Vertical Expandable Prosthetic Titanium Rib), which provides surgical expansion of the chest and correction of spinal deformities without inhibiting children’s growth.
The Children’s Hospital of Philadelphia is home to the Center for Cornelia de Lange Syndrome (CdLS) and Related Diagnoses, the largest program of its kind in the world, which has evaluated more than 1,000 children with CdLS.
The Children’s Hospital of Philadelphia has the largest and most comprehensive Experimental Therapeutics Program in the nation for pediatric cancer patients. We provide novel, targeted therapies not available at many other institutions, including the nation’s first proton beam therapy program conceived specifically for pediatric patients.
CHOP is a member of all three National Institutes of Health/National Cancer Institute-supported cooperative groups or consortia — Children’s Oncology Group (COG)-Phase I/II, New Approaches to Neuroblastoma Therapy (NANT) and Pediatric Brain Tumor Consortium (PBTC) — all of which have limited membership. The Hospital is also one of only 13 members of the Pediatric Pharmacology Research Unit (PPRU) Network, which facilitates and promotes pediatric labeling of new drugs or drugs already on the market in an effort to foster cooperative research efforts among academia, industry and health professionals.
The Children’s Hospital of Philadelphia’s Cancer Center is the world’s leading center for neuroblastoma, the most common pediatric solid tumor outside of the brain. We quickly translate laboratory work into clinical trials to advance improved therapies for children around the world. CHOP’s Cancer Center has the world’s most active program in providing 131I-MIBG therapy to patients with neuroblastoma, and has treated hundreds of patients on multiple clinical trials and led the efforts to prove this drug to be safe and effective.
The Children’s Hospital of Philadelphia’s Blood and Marrow Transplantation Program, one of the largest and oldest programs of its kind for children, is accredited by the Foundation for the Accreditation of Cellular Therapy (FACT), an organization with rigorous standards of practice for clinical, collection and processing facilities. Our program is also a National Cancer Institute Comprehensive Cancer Center, in collaboration with the Hospital of the University of Pennsylvania, and is a designated transplant center for the National Marrow Donor Program, which has strict standards for transplantation expertise and procedures.
Children’s Hospital’s Cancer Survivorship Program, founded in 1983, was the first program to track and provide long-term care for survivors of childhood cancer. Today, more than 500 children and adolescents are active in the program, which provides comprehensive care for the medical and psychosocial late effects experienced by cancer patients.
From its founding to the present day, Children’s Hospital has been at the forefront of countless research breakthroughs that have improved the lives of children throughout the world. See a timeline of our distinguished research history.
The Center for Applied Genomics, established at CHOP in 2006, is one of the world’s largest programs for detecting gene variations and linking them to particular illnesses, and the only such program entirely based at a pediatric hospital. Researchers at CHOP’s Center for Applied Genomics have discovered genes for many diseases, including autism, ADHD, obesity, diabetes, anorexia and neuroblastoma, a rare childhood cancer.